Samuelsson, John http://orcid.org/0000-0001-6010-3501
Bertilsson, Rebecka
Bülow, Erik http://orcid.org/0000-0002-9973-456X
Carlsson, Sanna
Åkesson, Sanna
Eliasson, Björn http://orcid.org/0000-0003-2569-4160
Hanas, Ragnar http://orcid.org/0000-0001-8372-030X
Åkesson, Karin http://orcid.org/0000-0003-2556-5094
Funding for this research was provided by:
The Joanna Cocozza Foundation
Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns
Linköping University
Article History
Received: 29 September 2023
Accepted: 27 November 2023
First Online: 22 January 2024
Data availability
: The de-identified individual participant datasets that underlie the results reported in the current study can be obtained from the corresponding author upon reasonable request.
: This study was funded by The Joanna Cocozza Foundation and Futurum - Academy for Health and Care, Region Jönköping County, Sweden. The study funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
: BE reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Mundipharma, NovoNordisk, RLS Global and Sanofi, all outside the submitted work. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: JS, KÅ and RH contributed to the study concept and design. JS and KÅ contributed to acquisition of data. JS, KÅ, RH, BE, SC and SÅ contributed to interpretation of data. RB and EB did the statistical analyses. JS had the primary responsibility for writing the paper. All authors reviewed and revised subsequent versions of the manuscript. All authors approved the final version of the manuscript. KÅ is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.